![]()
- Lesson From Dubai: Start Cutting Risk In Your Portfolio
- Iranian Seizure of British Yacht Pushes Oil Above $77
- Should Homeowners Be Able to Stop Paying Mortgage?
- Buffett's Predictions For Next Year—And Every Year
- The World's Biggest Debtor Nations
- Goldman Sachs Party Ban: No Gatherings of 12 or More
- Fed Tweaking Plan to Pull Money Back out of Economy
- Scientists Gone Wild: Climate Debate Turns Nasty
- Blue Nile CEO: Having 'Best Cyber Monday Ever'
- Nov. 30: Unusual Volume Leaders
- Why Careful Shoppers Are Great for the Box Office
- Blue Nile CEO: 'We're Having the Best Cyber Monday Ever'
- Best Online Retailers to Buy Now: Internet Analyst
- ESPN The Magazine’s Body Issue: A Financial Success
- Cyber Monday: The Last Vestige of Dotcom Hype
- Dubai Fear is 'Noise'—Stay Fully Invested: Strategist
- Tech Comes to Holiday Shopping's Rescue?
- Timeless and Time-Tested Warren Buffett Watch Predictions
MOST SHARED
- Timeless and Time-Tested Warren Buffett Watch Predictions
- Black Friday Sales Disappoint Investors; Amazon Up
- Governments Must Take Steps To Avoid More Dubais: El-Erian
- Goldman Sachs Party Ban: No Gatherings of 12 or More
- Blue Nile CEO: 'We're Having the Best Cyber Monday Ever'
- Nov. 30: Unusual Volume Leaders
- Get Paid Six Figures to Wear a T-Shirt?
- Oil Demand Sees Year-Over-Year Rise, First Since 2007
- BofA Aims to Clearly Spell Out Credit Card Terms
- Should Homeowners Be Able To Walk Away From Mortgage?
Swiss-based Roche said it was cutting production of influenza drug Tamiflu, seen as one of the best defences against a possible bird flu pandemic, because supply now exceeds demand.
The pharmaceutical group said it had increased capacity to more than 400 million treatments a year and that supply now significantly outstrips orders with signs of slowing sales to governments wanting to prepare for any outbreak.
The cutback would not affect Roche's expectations for sales of Tamiflu for stockpiling, at between 800 million Swiss francs ($665 million) to 1.2 billion francs ($1 billion) in 2007, said William Burns, head of the company's pharmaceuticals unit.
"Our guidance for the year is unchanged," Burns told reporters. "This is not a new signal on the sales outlook for Tamiflu."
Roche said the expansion of capacity meant it could now satisfy "significant additional orders" from governments and companies for Tamiflu.
Roche certificates, its most widely traded form of equity, were 0.5% lower at 232.30 francs in late trading.
The World Health Organization (WHO) and some countries have been stockpiling the drug in case the H5N1 bird flu strain, now mainly affecting poultry, mutates and begins to spread quickly among humans.
Roche will maintain its stock of intermediates and active pharmaceutical ingredients, so it would be ready to gear up to full production capacity if needed.
Sales to governments in the first quarter were slower than in the previous three months and Eugene Tierney, head of specialist sales at Roche's drugs unit, said that was the first indication of a tail off in government orders and demand.
The Basel-based company has so far received orders from governments amounting to about 215 million treatments.
- Ever wished your cab driver would stop chatting and just get to where you're going? Well, that moment is closer than ever.
- UPS is giving its customers the option to offset its carbon emissions when sending a package.
- Romania's presidential campaign has been rocked by a video that may show the president striking a 10-year-old boy.
- Raising alligators is hard work, and the fickle taste of rich consumers has just made it much harder, says the NY Times.
- A recent issue of ESPN Magazine was one of its top sellers ever, and it only took scantily clad athletes to make it happen.
- The continued real estate boom in China is partially fueled by a generational flood of newlyweds.










